HUT70172A - Novel aryl-acetamides, pharmaceutical compositions comprising them and method for producing thereof - Google Patents

Novel aryl-acetamides, pharmaceutical compositions comprising them and method for producing thereof

Info

Publication number
HUT70172A
HUT70172A HU9301325A HU9301325A HUT70172A HU T70172 A HUT70172 A HU T70172A HU 9301325 A HU9301325 A HU 9301325A HU 9301325 A HU9301325 A HU 9301325A HU T70172 A HUT70172 A HU T70172A
Authority
HU
Hungary
Prior art keywords
acetamides
producing
pharmaceutical compositions
novel aryl
novel
Prior art date
Application number
HU9301325A
Other languages
English (en)
Other versions
HU9301325D0 (en
HU214578B (hu
Inventor
Helmut Pruecher
Karl-August Ackermann
Gerd Bartoszyk
Rudolf Gottschlich
Hartmut Greiner
Andrew Barber
Christoph Seyfried
Frank Mauler
Manfred Stohrer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HU9301325D0 publication Critical patent/HU9301325D0/hu
Publication of HUT70172A publication Critical patent/HUT70172A/hu
Publication of HU214578B publication Critical patent/HU214578B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
HU9301325A 1992-05-09 1993-05-07 Eljárás aril-acetamidok, valamint hatóanyagként ezen vegyületeket tartalmazó gyógyászati készítmények előállítására HU214578B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4215213A DE4215213A1 (de) 1992-05-09 1992-05-09 Arylacetamide

Publications (3)

Publication Number Publication Date
HU9301325D0 HU9301325D0 (en) 1993-09-28
HUT70172A true HUT70172A (en) 1995-09-28
HU214578B HU214578B (hu) 1998-04-28

Family

ID=6458428

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9301325A HU214578B (hu) 1992-05-09 1993-05-07 Eljárás aril-acetamidok, valamint hatóanyagként ezen vegyületeket tartalmazó gyógyászati készítmények előállítására

Country Status (22)

Country Link
US (1) US5532266A (hu)
EP (1) EP0569802B1 (hu)
JP (1) JP3210771B2 (hu)
KR (1) KR100241637B1 (hu)
CN (1) CN1041087C (hu)
AT (1) ATE168368T1 (hu)
AU (1) AU662051B2 (hu)
BR (1) BR1100581A (hu)
CA (1) CA2095797C (hu)
CZ (1) CZ289961B6 (hu)
DE (2) DE4215213A1 (hu)
DK (1) DK0569802T3 (hu)
ES (1) ES2121030T3 (hu)
HK (1) HK1011990A1 (hu)
HU (1) HU214578B (hu)
NO (1) NO179789C (hu)
PL (1) PL173779B1 (hu)
RU (1) RU2125041C1 (hu)
SK (1) SK282646B6 (hu)
TW (1) TW372961B (hu)
UA (1) UA32543C2 (hu)
ZA (1) ZA933222B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137571A (en) * 1990-06-05 1992-08-11 Rohm And Haas Company Method for improving thickeners for aqueous systems
DE4407047A1 (de) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
WO1996006078A1 (en) * 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
WO1997046549A1 (en) * 1996-06-05 1997-12-11 Novartis Ag Anti-neurodegeneratively effective xanthene derivatives
MXPA99011298A (es) * 1997-07-14 2004-10-28 Adolor Corp Formulaciones farmaceuticas antiprurito de agonista kappa y metodo para tratar prurito con las mismas.
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2007207867B2 (en) * 2001-04-05 2009-09-24 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of bladder diseases
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
DE60327315D1 (de) 2002-05-17 2009-06-04 Tioga Pharmaceuticals Inc Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US6852713B2 (en) * 2003-04-16 2005-02-08 Adolor Corporation Lactam derivatives and methods of their use
US6992193B2 (en) 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US7160902B2 (en) * 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
US7288543B2 (en) * 2004-03-12 2007-10-30 Eli Lilly And Company Opioid receptor antagonists
AU2008232954A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
WO2011062052A1 (ja) * 2009-11-18 2011-05-26 日本ゼオン株式会社 フルオレン化合物、当該フルオレン化合物を含有する安定化剤及び組成物
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
JP7471818B2 (ja) 2016-08-18 2024-04-22 ヴィダック ファーマ リミテッド ピペラジン誘導体、医薬組成物、及びその使用方法
EP3558300B1 (en) 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) * 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) * 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3935371A1 (de) * 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
JPH05501551A (ja) * 1989-11-24 1993-03-25 スミスクライン　ビーチャム　ファルマシューティッチ　エッセ　ピ　ア アザ環式誘導体
GB8926560D0 (en) * 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals

Also Published As

Publication number Publication date
CN1079219A (zh) 1993-12-08
EP0569802B1 (de) 1998-07-15
DE4215213A1 (de) 1993-11-11
NO179789C (no) 1996-12-18
CZ289961B6 (cs) 2002-05-15
KR100241637B1 (ko) 2000-03-02
AU662051B2 (en) 1995-08-17
NO931681D0 (no) 1993-05-07
PL173779B1 (pl) 1998-04-30
KR930023340A (ko) 1993-12-18
HK1011990A1 (en) 1999-07-23
CZ82393A3 (en) 1994-02-16
SK282646B6 (sk) 2002-10-08
NO179789B (no) 1996-09-09
CA2095797A1 (en) 1993-11-10
DK0569802T3 (da) 1999-04-19
CA2095797C (en) 2007-09-18
HU9301325D0 (en) 1993-09-28
ES2121030T3 (es) 1998-11-16
TW372961B (en) 1999-11-01
PL298845A1 (en) 1994-01-10
ZA933222B (en) 1993-12-08
CN1041087C (zh) 1998-12-09
AU3834193A (en) 1993-11-11
JPH0649022A (ja) 1994-02-22
UA32543C2 (uk) 2001-02-15
HU214578B (hu) 1998-04-28
US5532266A (en) 1996-07-02
DE59308763D1 (de) 1998-08-20
SK46893A3 (en) 1994-04-06
ATE168368T1 (de) 1998-08-15
JP3210771B2 (ja) 2001-09-17
RU2125041C1 (ru) 1999-01-20
BR1100581A (pt) 2000-08-01
NO931681L (no) 1993-11-10
EP0569802A1 (de) 1993-11-18

Similar Documents

Publication Publication Date Title
HUT70172A (en) Novel aryl-acetamides, pharmaceutical compositions comprising them and method for producing thereof
RU93004806A (ru) Арилацетамиды, способ их получения и применения, фармацевтическая композиция
EP0530505A3 (en) Hydantoin derivatives
MX9501157A (es) Acetamidas, proceso para su preparacion y preparaciones farmaceuticas que las contienen.
EP0630260A4 (en) POLYSACCHARIDE-PROTEIN CONJUGATES.
GR3022079T3 (en) Preparation of substituted piperidines
HUT66234A (en) Process to prepare 4,13-dioxabicyclo(8.2.1)-tridecenon-derivatives and pharmaceutical compositions containing them
EP0450420A3 (en) Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments
HU9600360D0 (en) New bis-naphthalimides for the treatment of cancer
HUT54682A (en) Process for producing 13-bromine- and 13,14-dibromine-ergoline derivatives and pharmaceutical preparatives containing these compounds
TW232011B (hu)
HU9600300D0 (en) Thiocarbamoyl derivatives using as antimicrobial agents and process for producing of these
IL107142A0 (en) Tetrahydroindazolone pharmaceutical compositions

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: TIOGA PHARMACEUTICALS, INC., US

Free format text: FORMER OWNER(S): MERCK PATENT GMBH., DE